|
1
|
Kinoshita Y and Saeki H: A review of toxic
epidermal necrolysis management in Japan. Allergol Int. 66:36–41.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ordoñez L, Salgueiro E, Jimeno FJ and
Manso G: Spontaneous reporting of Stevens-Johnson syndrome and
toxic epidermal necrolysis associated with antiepileptic drugs. Eur
Rev Med Pharmacol. 19:2732–2737. 2015.PubMed/NCBI
|
|
3
|
Gaghan LJ, Coates MM, Crouse LN, Miedema
J, Mervak JE and Ziemer CM: Photodistributed toxic epidermal
necrolysis: Case report and review of current literature. JAMA
Dermatol. 158:787–790. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Maity S, Banerjee I, Sinha R, Jha H, Ghosh
P and Mustafi S: Nikolsky's sign: A pathognomic boon. J Family Med
Prim Care. 9:526–530. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lerch M, Mainetti C, Terziroli
Beretta-Piccoli B and Harr T: Current perspectives on
stevens-johnson syndrome and toxic epidermal necrolysis. Clin Rev
Allergy Immunol. 54:147–176. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen CB, Abe R, Pan RY, Wang CW, Hung SI,
Tsai YG and Chung WH: An updated review of the molecular mechanisms
in drug hypersensitivity. J Immunol Res.
2018(6431694)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Torrelo A: Methylprednisolone aceponate
for atopic dermatitis. Int J Dermatol. 56:691–697. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chinese Medical Association, Chinese
Medical Journals Publishing House, Chinese Society of Dermatology,
Chinese Society of General Practice, Editorial Board of Chinese
Journal of General Practitioners of Chinese Medical Association,
Expert Group of Guidelines for Primary Care of Skin and Venereal
Disease. Guideline for primary care of drug eruption (2022). Chin J
Gen Pract. 21:804–813. 2022.(In Chinese).
|
|
9
|
Wilkerson RG: Drug hypersensitivity
reactions. Emerg Med Clin North Am. 40:39–55. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ueta M: Susceptibility genes and HLA for
cold medicine-related SJS/TEN with SOC. Front Genet.
13(912478)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tassaneeyakul W, Prabmeechai N, Sukasem C,
Kongpan T, Konyoung P, Chumworathayi P, Tiamkao S, Khunarkornsiri
U, Kulkantrakorn K, Saksit N, et al: Associations between HLA class
I and cytochrome P450 2C9 genetic polymorphisms and
phenytoin-related severe cutaneous adverse reactions in a Thai
population. Pharmacogenet Genomics. 26:225–234. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grünwald P, Mockenhaupt M, Panzer R and
Emmert S: Erythema multiforme, Stevens-Johnson syndrome/toxic
epidermal necrolysis-diagnosis and treatment. J Dtsch Dermatol Ges.
18:547–553. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Schneider JA and Cohen PR: Stevens-Johnson
Syndrome and toxic epidermal necrolysis: A concise review with a
comprehensive summary of therapeutic interventions emphasizing
supportive measures. Adv Ther. 34:1235–1244. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Garcia-Doval I, LeCleach L, Bocquet H,
Otero XL and Roujeau JC: Toxic epidermal necrolysis and
Stevens-Johnson syndrome: Does early withdrawal of causative drugs
decrease the risk of death? Arch Dermatol. 136:323–327.
2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rizzo JA, Johnson R and Cartie RJ:
Pediatric toxic epidermal necrolysis: Experience of a Tertiary Burn
Center. Pediatr Dermatol. 32:704–709. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Noe MH and Micheletti RG: Diagnosis and
management of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Clin Dermatol. 38:607–612. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jacobsen A, Olabi B, Langley A, Beecker J,
Mutter E, Shelley A, Worley B, Ramsay T, Saavedra A, Parker R, et
al: Systemic interventions for treatment of Stevens-Johnson
syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN
overlap syndrome. Cochrane Database Syst Rev.
3(CD013130)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zimmermann S, Sekula P, Venhoff M,
Motschall E, Knaus J, Schumacher M and Mockenhaupt M: Systemic
immunomodulating therapies for stevens-johnson syndrome and toxic
epidermal necrolysis: A systematic review and meta-analysis. JAMA
Dermatol. 153:514–522. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chafranska L, Saunte DM, Behrendt N,
Nygaard U, Christensen RJ, Sand C and Jemec GB: Pediatric toxic
epidermal necrolysis treated successfully with infliximab. Pediatr
Dermatol. 36:342–345. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Da W, Zhu J, Wang L and Lu Y: Adalimumab
for Crohn's disease after infliximab treatment failure: A
systematic review. Eur J Gastroenterol Hepatol. 25:885–891.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zeng C, Liao Q, Hu Y, Shen Y, Geng F and
Chen L: The role of periplaneta americana (Blattodea: Blattidae) in
modern versus traditional Chinese medicine. J Med Entomol.
56:1522–1526. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fu S, Chen J, Zhang C, Shi J, Nie X, Hu Y,
Fu C, Li X and Zhang J: Gastroprotective effects of periplaneta
Americana L. extract against ethanol-induced gastric ulcer in mice
by suppressing apoptosis-related pathways. Front Pharmacol.
12(798421)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Barron SJ, Del Vecchio MT and Aronoff SC:
Intravenous immunoglobulin in the treatment of Stevens-Johnson
syndrome and toxic epidermal necrolysis: A meta-analysis with
meta-regression of observational studies. Int J Dermatol.
54:108–115. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Huang YC, Chien YN, Chen YT, Li YC and
Chen TJ: Intravenous immunoglobulin for the treatment of toxic
epidermal necrolysis: A systematic review and meta-analysis. G Ital
Dermatol Venereol. 151:515–524. 2016.PubMed/NCBI
|
|
25
|
Yang Y, Xu J, Li F and Zhu X: Combination
therapy of intravenous immunoglobulin and corticosteroid in the
treatment of toxic epidermal necrolysis and Stevens-Johnson
syndrome: A retrospective comparative study in China. Int J
Dermatol. 48:1122–1128. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Al Rajaibi R, Al Rumhi T and Al Abri AM:
Carbamazepine-Induced stevens-johnson syndrome/toxic epidermal
necrolysis overlap treated successfully with oral cyclosporin: Case
report and literature review. Sultan Qaboos Univ Med J. 21:491–494.
2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo
L, Hou Y, An J, Wang X, Yan B, et al: Successful treatment of toxic
epidermal necrolysis using plasmapheresis: A prospective
observational study. J Crit Care. 42:65–68. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Clark WF and Huang SS: Introduction to
therapeutic plasma exchange. Transfus Apher Sci. 58:228–229.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Thakor AS, Burke A, Handfield-Jones S,
Sinha A, Palmer M and Burns A: Toxic epidermal necrolysis and
neutropaenia: Complications of omeprazole. Australas J Dermatol.
50:207–210. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lin CY, Wang CW, Hui CR, Chang YC, Yang
CH, Cheng CY, Chen WW, Ke WM and Chung WH: Delayed-type
hypersensitivity reactions induced by proton pump inhibitors: A
clinical and in vitro T-cell reactivity study. Allergy. 73:221–229.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Trayes KP, Love G and Studdiford JS:
Erythema multiforme: Recognition and management. Am Fam Physician.
100:82–88. 2019.PubMed/NCBI
|
|
32
|
Soares A and Sokumbi O: Recent updates in
the treatment of erythema multiforme. Medicina (Kaunas).
57(921)2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Rykiel K, Melchor J, Motie I, Mulles K and
Farhangi V: Recurrent erythema multiforme major following COVID-19
infection. Cureus. 15(e42646)2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lu X, Hu R, Peng L, Liu M and Sun Z:
Efficacy and safety of adalimumab biosimilars: Current critical
clinical data in rheumatoid arthritis. Front Immunol.
12(638444)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yamamoto T: An update on adalimumab for
pyoderma gangrenosum. Drugs Today (Barc). 57:535–542.
2021.PubMed/NCBI View Article : Google Scholar
|
